October 2014

From a limited first meeting in the late 1990s that included the leaders of a dozen large group practices, LUGPA has grown so much that its annual meeting this November will include up to 550 physicians and 200 administrators, filling the organization's usual Chicago venue to capacity and necessitating a move to a larger space next year.

A round-up of new drugs that are being investigated as treatments for genitourinary cancers.

The 12-month countdown to the adoption of ICD-10 has begun. ICD-10 represents the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (usually referred to as "ICD"), now overseen by the World Health Organization (WHO).

Over the past 6 months, we have had two studies that will profoundly affect our management of advanced prostate cancer patients.

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.

When it comes to biomarker-based cancer treatment, there are nearly endless avenues to explore.

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the implementation of six drugs approved since their previous recommendations were issued in 2007, as well as on older drugs.

The rate of severe urinary tract infections following transrectal ultrasound-guided biopsy for the detection of prostate cancer has been on the rise in Sweden

If a man has a certain pattern of baldness when he reaches 45 years of age, he faces a 45% higher risk of developing aggressive prostate cancer later in life than does a man with no baldness at that age.

Robotic-assisted radical prostatectomy (RARP) was widely adopted in the United States between 2003 and 2010, mainly among high-volume surgeons.